BeStock  
Stocks › Biotechnology › BCAX

Bicara Therapeutics BCAX

US equityMarket cap rank #3186Biotechnology
$16.42 −$0.14 (-0.85%)
Pre-market · Oct 8, 8:20 am ET · After hours $16.42 0.00%
Open$16.44
Prev close$16.56
Day range$16.25 – $17.11
Volume915.6K
Market cap$1.09B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership115.8%-1.23 pts vs. prior quarter
Institutions holding208-2 vs. prior quarter
Insider trades (recent)10 buys / 40 sellsNet selling
Short interest16.91% of floatDays to cover 22.6 · as of 15 Sep 2026
Short-sale volume share18.0%5-day average of daily volume

Short-sale volume as % of daily volume

11%15%19%23%Sep '26Sep '26Oct '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$1.02M (4 inflow days, 16 outflow days).

Net flow by order size, last 20 sessions

+$3.0MSuper−$2.0MBig−$2.3MMid−$2.8MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 48.2% of shares outstanding.

Largest holders

  • T. Rowe Price Group, Inc.12.46%
  • RA Capital Management, L.P.10.97%
  • Artal Group S.A.8.47%
  • Biocon Limited8.35%
  • Vestal Point Capital, LP7.93%
  • Deep Track Capital, LP6.20%
  • BlackRock5.82%
  • Janus Henderson Group plc4.79%

By investor type

  • Mutual Fund47.26%
  • VC/PE Fund41.69%
  • Hedge Fund15.46%
  • Public Company10.30%
  • Individual/Insider1.84%
  • Private Company0.79%
  • Government Pension Fund0.15%
  • Insurance Company0.14%

Reported short interest has risen from 15.40% to 16.91% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Nuveen Asset Management LLC Insurance Company 2026/Q3 +90,637 0.1%
BlackRock Mutual Fund 2026/Q3 +1,004,383 5.8%
J.P. Morgan Asset Management, Inc. Mutual Fund 2026/Q3 +828,979 1.5%
State Street Global Advisors Mutual Fund 2026/Q3 +629,532 3.1%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +539,405 3.8%
Dimensional Fund Advisors Mutual Fund 2026/Q3 +352,463 0.7%
Franklin Resources Mutual Fund 2026/Q3 +346,166 2.9%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +331,729 1.8%
Columbia Management Investment Advisers, LLC Mutual Fund 2026/Q3 +272,931 0.4%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +260,757 12.5%
Walleye Capital LLC Hedge Fund 2026/Q3 +245,218 0.5%
SEB Funds AB Mutual Fund 2026/Q3 +232,156 0.4%
D. E. Shaw & Co., L.P. Hedge Fund 2026/Q3 +221,250 0.8%
Northern Trust Global Investments Mutual Fund 2026/Q3 +140,772 0.6%
Candriam, Société En Commandite Par Actions Mutual Fund 2026/Q3 +134,558 0.6%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
7 Sep 2026 Ryan Cohlhepp President Derivative Exercise and Sale -17,500 $23.43 181,641
7 Sep 2026 Ivan Hyep Chief Financial Officer Intent to Sell (Form 144) -12,500 $22.64 –
9 Aug 2026 Ryan Cohlhepp President Derivative Exercise and Sale -18,750 $27.98 181,641
9 Aug 2026 Claire Mazumdar Clemon Chief Executive Officer Derivative Exercise and Sale -10,000 $27.98 362,152
9 Aug 2026 Ivan Hyep Chief Financial Officer Derivative Exercise and Sale -12,500 $27.97 129,855
27 Jul 2026 Christy Oliger Independent Director Other Derivative Acquisition +38,950 $26.88 38,950
27 Jul 2026 Jeremy Bender Independent Director Other Derivative Acquisition +38,950 $26.88 38,950
9 Jul 2026 Claire Mazumdar Clemon Chief Executive Officer Derivative Exercise and Sale -10,000 $29.68 362,152
8 Jul 2026 Ryan Cohlhepp President Automatic Disposition -10,000 $30.35 181,641
7 Jul 2026 Ryan Cohlhepp President Derivative Exercise and Sale -18,750 $28.76 181,641
7 Jul 2026 David Raben Chief Medical Officer Intent to Sell (Form 144) -50,000 $28.56 –
7 Jul 2026 Ivan Hyep Chief Financial Officer Automatic Disposition -15,500 $30.31 129,855
7 Jul 2026 Ivan Hyep Chief Financial Officer Derivative Exercise and Sale -12,500 $28.60 129,855
24 Jun 2026 David Raben Chief Medical Officer Intent to Sell (Form 144) -50,000 $26.49 –
8 Jun 2026 Michael Powell Independent Chairperson Other Derivative Acquisition +19,475 $20.56 19,475
8 Jun 2026 Kiran Mazumdar-Shaw Independent Director Other Derivative Acquisition +19,475 $20.56 19,475
8 Jun 2026 RA Capital Management, L.P. Other Derivative Acquisition +19,475 $20.56 19,475
8 Jun 2026 Scott Robertson Independent Director Other Derivative Acquisition +19,475 $20.56 19,475
8 Jun 2026 Christopher Bowden Independent Director Other Derivative Acquisition +19,475 $20.56 19,475
8 Jun 2026 Kathryn Haviland Independent Director Other Derivative Acquisition +19,475 $20.56 19,475

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
15 Sep 2026 11,191,724 16.9% 22.6
31 Aug 2026 10,845,514 16.4% 22.1
14 Aug 2026 10,463,188 15.8% 13.3
31 Jul 2026 9,597,404 14.6% 20.4
15 Jul 2026 9,315,906 14.2% 12.7
30 Jun 2026 10,121,649 15.4% 7.3

Discussion

No comments yet — be the first to weigh in on BCAX.

Leave a comment

Scroll to Top